atau cari berdasarkan hari
Biotis Pharmaceuticals Indonesia is producing a pilot scale of the Merah Putih Vaccine using seeds produced by Airlangga University.
BRIN official Erry Ricardo said Unair and Eijkman are the two leading institutions in the development of the Merah Putih Vaccine.
BRIN has spent up to Rp200 billion for the development of the home-grown merah putih vaccine to combat COVID-19.
BPOM grants a certificate of Good Manufacturing Practices (GMP) Fill and Finish Facility for the production of Covid-19 vaccine candidates.
Head of BRIN explains the major challenges facing Indonesia's inaugural home-grown Covid-19 vaccine, the Merah Putih vaccine.
Eijkman Institute for Molecular Biology Head, Amin Soebandrio, said the Merah Putih vaccine will be tested against various virus variants.
The Health Ministry is monitoring the developments in the Nusantara vaccine which has now become the public limelight again.
Rector of Universitas Airlangga (Unair) Surabaya, Mohammad Nasih, expressed optimism that the Merah Putih vaccine will be ready for use in 2022.
BPOM Head Penny Lukito said the mass production of homegrown COVID-19 vaccine dubbed the Merah Putih vaccine was hoped to commence in early 2022.
Eijkman Institute reported the development of the home-grown Merah Putih vaccine.
The Indonesian Institute of Sciences (LIPI) was targeting to hand over its Covid-19 Merah Putih vaccine seed to the vaccine industry in early 2022.
President Joko "Jokowi" Widodo said the government continues to monitor the research development of homegrown Covid-19 vaccines.
The Indonesian government has four ways to meet the supply of Covid-19 vaccines.
President Joko "Jokowi" Widodo said the government was continually striving to obtain the Covid-19 vaccine from various countries.
Minister Erick Thohir said state ministries and private institutions are working hard to produce the Merah Putih vaccine by 2022.
The Eijkman Institute of Molecular Biology has the swiftest progress in developing the home grown 'Merah Putih vaccine' for Covid-19.